BIOMAT Database Logo BIOMAT Database Logo

Regulation of PDE5 expression in normal prostate, benign prostatic hyperplasia, and adenocarcinoma. 2020

C Bisegna, and G L Gravina, and F Pierconti, and M Martini, and L Larocca, and P Rossi, and P Grimaldi, and S Dolci, and S Di Stasi, and E A Jannini
Section of Anatomy, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.

Type 5 phosphodiesterase (PDE5) expression in the normal and pathological prostate is controversial. This study aimed at identifying the cell type/s, if any, expressing PDE5 in human healthy or pathological prostate sections in order to further validate the rationale of PDE5 inhibitor (PDE5i) treatment of benign prostatic hyperplasia (BPH) and their safety in the treatment of erectile dysfunction following prostate cancer (PCa) surgery. By immunohistochemical analysis, we studied PDE5 expression in tissue microarrays containing sections obtained from healthy, BPH, and PCa samples. Our results showed that PDE5 is barely expressed in the epithelial or stromal compartment of normal human prostates, but it is highly expressed in the stromal compartment of BPH sections. We also found that a low but significant number of PCa samples (22%) expressed PDE5 in the epithelial cancer cells but not in stromal cells and that such expression was not correlated with the tumor aggressiveness, according to their Gleason score. PDE5 overexpression in the stromal compartment of BPH samples supports the rationale of PDE5 as a target in lower urinary tract symptoms of BPH. PDE5 expression in a significant percentage of PCa samples but the lack of correlation with the Gleason score suggests that this enzyme is not correlated with tumor aggressiveness; however, a role of PDE5 in the minimal residual disease of PCa cannot be excluded.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011467 Prostate A gland in males that surrounds the neck of the URINARY BLADDER and the URETHRA. It secretes a substance that liquefies coagulated semen. It is situated in the pelvic cavity behind the lower part of the PUBIC SYMPHYSIS, above the deep layer of the triangular ligament, and rests upon the RECTUM. Prostates
D011470 Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both. Adenoma, Prostatic,Benign Prostatic Hyperplasia,Prostatic Adenoma,Prostatic Hyperplasia, Benign,Prostatic Hypertrophy,Prostatic Hypertrophy, Benign,Adenomas, Prostatic,Benign Prostatic Hyperplasias,Benign Prostatic Hypertrophy,Hyperplasia, Benign Prostatic,Hyperplasia, Prostatic,Hyperplasias, Benign Prostatic,Hypertrophies, Prostatic,Hypertrophy, Benign Prostatic,Hypertrophy, Prostatic,Prostatic Adenomas,Prostatic Hyperplasias, Benign,Prostatic Hypertrophies
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

C Bisegna, and G L Gravina, and F Pierconti, and M Martini, and L Larocca, and P Rossi, and P Grimaldi, and S Dolci, and S Di Stasi, and E A Jannini
Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia.
January 2001, Anticancer research,
C Bisegna, and G L Gravina, and F Pierconti, and M Martini, and L Larocca, and P Rossi, and P Grimaldi, and S Dolci, and S Di Stasi, and E A Jannini
Alcohol dehydrogenase expression patterns in normal prostate, benign prostatic hyperplasia, and prostatic adenocarcinoma in African American and Caucasian men.
May 2022, The Prostate,
C Bisegna, and G L Gravina, and F Pierconti, and M Martini, and L Larocca, and P Rossi, and P Grimaldi, and S Dolci, and S Di Stasi, and E A Jannini
Expression of acid cysteine proteinase inhibitor (ACPI) in the normal human prostate, benign prostatic hyperplasia and adenocarcinoma.
July 1995, International journal of cancer,
C Bisegna, and G L Gravina, and F Pierconti, and M Martini, and L Larocca, and P Rossi, and P Grimaldi, and S Dolci, and S Di Stasi, and E A Jannini
Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma.
April 2009, Experimental and molecular pathology,
C Bisegna, and G L Gravina, and F Pierconti, and M Martini, and L Larocca, and P Rossi, and P Grimaldi, and S Dolci, and S Di Stasi, and E A Jannini
Osteopontin expression in prostate cancer and benign prostatic hyperplasia.
January 1999, Urologia internationalis,
C Bisegna, and G L Gravina, and F Pierconti, and M Martini, and L Larocca, and P Rossi, and P Grimaldi, and S Dolci, and S Di Stasi, and E A Jannini
Antigenic cross reactivity between benign prostatic hyperplasia and adenocarcinoma of prostate.
January 1975, Urology,
C Bisegna, and G L Gravina, and F Pierconti, and M Martini, and L Larocca, and P Rossi, and P Grimaldi, and S Dolci, and S Di Stasi, and E A Jannini
Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia.
December 1992, British journal of cancer,
C Bisegna, and G L Gravina, and F Pierconti, and M Martini, and L Larocca, and P Rossi, and P Grimaldi, and S Dolci, and S Di Stasi, and E A Jannini
Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia.
January 1994, British journal of cancer,
C Bisegna, and G L Gravina, and F Pierconti, and M Martini, and L Larocca, and P Rossi, and P Grimaldi, and S Dolci, and S Di Stasi, and E A Jannini
Caspase 3 expression in benign prostatic hyperplasia and prostate carcinoma.
May 2001, The Prostate,
C Bisegna, and G L Gravina, and F Pierconti, and M Martini, and L Larocca, and P Rossi, and P Grimaldi, and S Dolci, and S Di Stasi, and E A Jannini
Expression of periglandular tenascin-C and basement membrane laminin in normal prostate, benign prostatic hyperplasia and prostate carcinoma.
June 1998, British journal of urology,
Copied contents to your clipboard!